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PURPOSE. Fusarium solani (F. solani) keratitis is a potentially sight-threatening fungal infection
of the cornea. Antimicrobial peptides (AMPs), such as human b-defensins (hBDs) and
cathelicidins, essential components of the immune system, likely have a protective role
against F. solani keratitis. We examined the role of pattern recognition receptors (PRRs),
Dectin-1, and TLR2 in F. solani–induced modulation of AMP expression in vitro.
METHODS. Human corneal epithelial cells (HCECs) were exposed to heat-inactivated F. solani
or pathogen-associated molecular patterns (PAMPs) of F. solani (Zymosan or Zymosan
Depleted) for 6, 12, or 24 hours following which AMP mRNA and protein levels were
determined. Involvement of TLR2 and Dectin-1 was confirmed by using siRNA knock-down
(TLR2 and Dectin-1) or chemical inhibitor BAY 61-3606 (Dectin-1). The functional
significance of AMP upregulation was tested using culture supernatant from F. solani or
PAMP-treated HCECs against F. solani in the presence of hBD2 or LL37 neutralizing antibody.
RESULTS. We confirm that HCECs express Dectin-1 and TLR2. HCECs demonstrated
upregulation of AMPs hBD2 and cathelicidin LL37 following exposure to heat-inactivated F.
solani or PAMPs. TLR2 and Dectin-1 knockdown and BAY 61-3606 treatment decreased AMP
mRNA upregulation confirming PRR involvement. The culture supernatant from F. solani or
PAMP-treated HCECs showed substantial killing of F. solani and hBD2 or LL37 neutralizing
antibody significantly decreased this effect implicating involvement of these AMPs.
CONCLUSIONS. These findings demonstrate that Dectin-1 and TLR2 have an important role in
regulating F. solani-induced AMP expression in corneal epithelial cells.
Keywords: F. solani, keratitis, defensins, cathelicidins, pattern recognition receptors
Fungal keratitis (keratomycosis) is a potentially devastatingocular infection that may result in permanent visual
impairment and even blindness. It is endemic in tropical
regions, such as parts of Central and South America, Africa,
Asia, and in the southeastern and central United States.1,2
Fungal keratitis is linked historically to ocular trauma resulting
from vegetative matter contaminated with soil as reported with
most cases from developing countries, such as India and
Ghana.3,4 However, contact lens wear is recognized as the
major predisposing factor for fungal keratitis in industrialized
nations. For example, in the United States, contact lens wear
accounts for 37% and ocular trauma for 25% of fungal keratitis
cases.1 While a range of fungi have been identified as the
culprit, Fusarium species are the most commonly isolated
organisms in fungal keratitis. F. solani in particular has been
implicated as the causative pathogen in more than 30% of
cases2,5–7 and was identified as the culprit in the 2004 to 2006
worldwide epidemic associated with contact lens wear.8,9
Despite F. solani keratitis being a critical cause of vision loss
and blindness in developing and developed countries, only a
few published studies have addressed the underlying pathology
and host defense mechanisms to protect and limit the damage
to the cornea.
Antimicrobial peptides (AMPs) form an integral part of the
innate immune system and provide defense against a range of
pathogens as well as modulating immune responses and wound
healing.10 At the human ocular surface the primary AMPs
produced by the epithelial cells are b-defensins (hBDs) and the
cathelicidin LL37.11 These help provide a baseline defense
against invading pathogens and several are upregulated in
response to infection and inflammatory stimuli.12–14 We have
shown previously that there is increased expression of b-
defensins and cathelicidin in a murine model of F. solani
keratitis and that severity of infection is increased in AMP
knockout or knockdown mice, thus implying an important role
for AMPs in defense against F. solani infection.15
To better understand the mechanism underlying F. solani
stimulation of corneal AMP expression, our studies focused on
two pattern recognition receptors (PRRs), Toll-like receptor 2
(TLR2) and Dectin-1, as likely primary mediators of enhanced
AMP expression. TLR2 is one of several TLRs expressed by the
ocular surface epithelia16 and can interact with a number of
fungal-associated pathogen molecular patterns (PAMPs) such as
b-glucans and phospholipomannans.17 TLR2 activation is
known to increase human corneal epithelial (HCEC) AMP
expression18 and in part mediate proinflammatory cytokine
secretion induced by HCEC exposure to inactive hyphal
fragments of F. solani.19 TLR2 also is one of several TLRs
showing enhanced expression in humans corneas infected by F.
solani.20 Dectin-1 belongs to the C-type lectin-like receptor
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family, which are the primary PRR group for the recognition of
fungi.21 It recognizes b-1,3-glucans from the cell wall of many
fungi and, like some other C-type lectins, signals NF-kB
activation through the syk/CARD9 pathway.22 Dectin-1 is
expressed by HCEC23,24 and it is upregulated in Fusarium-
infected human corneas.25 Little is known about the role of
Dectin-1 in F. solani keratitis although it has been reported to
mediate increased HCEC IL-8 expression in response to
Aspergillus fumigatus26 and is implicated as the major PRR
on resident corneal macrophages and dendritic cells that
triggers the immune response in a murine model of Aspergillus
keratitis.27 We investigated a novel role for Dectin-1 in
mediating F. solani-stimulated AMP expression by HCEC as
well as collaboration between Dectin-1 and TLR2 as has been
shown in other antifungal responses.22
MATERIALS AND METHODS
Fungi
F. solani (strain 36031; American Type Culture Collection,
Manassas, VA, USA), a pathogenic strain obtained from a
patient with F. solani keratitis that is capable of producing
murine keratomycosis,15 was cultured in Sabouraud dextrose
(SD) agar (Difco, Detroit, MI, USA) for 3 days at 308C. A colony
of F. solani was inoculated into 4 mL of SD broth and grown
aerobically overnight with shaking (250 rpm) at 308C. Then,
250 lL of fungal suspension were inoculated into 50 mL of
fresh SD broth at 308C, 250 rpm for 48 hours to expand the
culture. The turbidity of this hyphal suspension was adjusted
to an optical density (OD) of 1 at 600 nm which corresponds
to approximately 5 3 105culturable units (CU). The hyphal
suspension then was diluted by centrifuging at 300g for 5
minutes, and resuspending in media to yield 13 105 CU/ mL.
Aliquots (100 lL) were heat-inactivated by incubating the
suspension at 1008C for 20 minutes. The aliquots were stored
at 808C until used in an experiment.
Human Corneal Epithelial Cells
Telomerase modified human corneal epithelial cells (hTCEpi)28
were grown at 378C with 5% CO2 in KG-2 keratinocyte growth
medium-2 (Lonza, Houston, TX, USA) in the presence of
growth factors and 50 lg/mL Normocin (InvivoGen, San Diego,
CA, USA). Findings from some experiments were confirmed in
primary cultured HCEC (passages 1 and 2) prepared from pairs
of normal cadaveric corneas received within 2 to 5 days of
death based on a method previously described.12 Cells were
plated in 6-well plates and treated with heat-inactivated F.
solani (prepared as described above) or PAMPs Zymosan,
Zymosan Depleted (InvivoGen) or the combination of the two
at 10 lg/mL for 6, 12, or 24 hours. In PRR knockdown
experiments 10 nM nonspecific or 3 different specific TLR2
(#1-s168, #2-s169, and #3-s170) or Dectin-1 siRNAs (#1-s34783,
#2-s34785, and #3-s227204; Ambion, Austin, TX, USA) were
tested. The siRNA, which demonstrated the highest percent
knockdown, was reconfirmed using RT-PCR and then used in
subsequent experiments. Briefly, hTCEpi cells were treated
with HiPerFect transfection reagent (Qiagen, Valencia, CA,
USA) as vehicle, 10 nM nonspecific or TLR2 (#3-s170), or
Dectin-1 siRNAs (#3-s227204) for 48 hours and heat-inactivated
F. solani for the final 6 or 24 hours, following which cells were
processed for mRNA or protein quantitation. In some
experiments cells were treated for 48 hours with 10 lM BAY
61-3601 (Emd Biosciences, Inc., San Diego, CA, USA) to block
Syk, a known mediator of Dectin-1 activity.29,30 Culture
supernatants were harvested for protein analysis by immuno-
blot or to test for antifungal activity. Cell lysates were collected
to determine mRNA levels for the AMPs hBD-1, -2, -3, and LL37.
RT-Polymerase Chain Reaction
Relative-quantitative real-time PCR was used to study AMP
expression. Total RNA from primary HCECs and hTCEpi cells
was extracted using an RNeasy Mini Kit (Qiagen) and
quantified using a NanoDrop 2000 spectrophotometer (Ther-
mo Fisher Scientific, Wilmington, DE, USA). RNA elution
columns were DNAse (Qiagen) treated before RNA elution to
avoid genomic DNA contamination. Two lg of total RNA were
reverse transcribed to cDNA using SuperScript III First-Strand
Synthesis System (Invitrogen, Carlsbad, CA, USA). RNAse free-
water in place of RNA served as a no-template control and
reactions without reverse transcriptase served as a no-RT
control. Relative-quantitative real-time PCR amplification was
performed using SYBR Green QPCR Mastermix kits (Strata-
gene, Santa Clara, CA, USA) with specific primer sequences as
described previously,13,18 at optimized concentrations. Primer
sequences used for RPL-27, Dectin-1, and TLR2 were as
follows: RPL-27 Forward: ATCGCCAAGAGACAAAGATAA, RPL-
27 Reverse: TCTGAAGACATCCTTATTGAC; Dectin-1 Forward:
ACTCTCAAAGCAATACCAGGA, Dectin-1 Reverse: CGCCAAG
GAGGAGATGCA; TRL2 Forward: CCTGGCCCTCTCTACAAA
CTT, TLR2 Reverse: ACTGTGTATTCGTGTGCTGGATA. The
PCR reaction included an initial 10-minute denaturation at
958C, then amplification was performed for 40 cycles:
denaturation, 958C for 30 seconds; annealing, 568C for 1
minute; and extension, 728C for 30 seconds. Data analysis was
performed using the Stratagene Mx3005p software and
disassociation melt curves were analyzed to ensure reaction
specificity. Amplified gene products were normalized to
RPL27, the internal control, and calibrated to the untreated
samples. The control samples were normalized to one and the
relative change of treated versus control samples was
determined. For each experiment, the samples were analyzed
in triplicate and the mean relative quantity of AMP expression
was calculated.
One step RT-PCR was used to investigate expression and
knockdown of Dectin-1 and TLR2. Total RNA from the samples
was extracted as described previously.18 RT-PCR was per-
formed using a Superscript One-step RT-PCR kit (Qiagen) with
40 cycles of amplification: denaturation, 948C for 1 minute;
annealing, 588C for 1 minute; extension at 728C for 2 minutes.
RT-PCR products were separated on 1.8% agarose gels and
were visualized using an Alpha Imager Gel documentation
system (Alpha Innotec, San Leandro, CA, USA).
Immunoblotting and Flow Cytometry
AMPs hBD2 and LL37 were detected in cell culture superna-
tants by immunoblot as described previously.18 hTCEpi cells
were treated with heat-inactivated F. solani or PAMPs for 24
hours and culture supernatants were collected, centrifuged at
1400g for 2 minutes to remove cell debris, and the samples
were stored at808C until analysis. Samples were blotted onto
PVDF membranes using a microfiltration apparatus (Biodot,
Irvine, CA, USA) then the membrane was incubated for 1 hour
at room temperature with Tris-buffered saline (TBS) containing
5% nonfat powdered milk to block the nonspecific binding
sites. The membrane then was incubated with rabbit anti-
human hBD2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
or LL37 (donated by R. I. Lehrer) diluted 1 to 1000 in TBS
containing 5% nonfat powdered milk, 5% goat serum, and 0.1%
Tween 20 overnight at 48C. The membrane then was washed
(6 3 5 minutes; TBST) and incubated for 45 minutes at room
temperature with a horseradish peroxidase–conjugated goat
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anti-rabbit antibody (Jackson Laboratories, West Grove, PA,
USA), diluted 1:50,000 for LL37 and 1:10,000 for hBD2 in TBS
containing 5% nonfat powdered milk.
Western blotting was performed to detect Dectin-1 or TLR2
and expression of Syk and phosphorylated-Syk in cell lysates.
Cells were lysed using radioimmunoprecipitation assay buffer
(RIPA buffer) for Dectin-1 and TLR2 immunoblotting and NP40
cell lysis buffer for the Syk and p-Syk assay. Protein quantitation
was performed using a BCA assay kit (Fischer, Windsor, CT,
USA). Equal amounts of protein (30 lg for Dectin-1 and TLR2
or 20 lg for Syk and p-Syk) were mixed with loading buffer and
separated on 4% to 20% precast-polyacrylamide gels (Bio-Rad
Laboratories, Hercules, CA, USA). The proteins then were
transferred onto 0.4 lm nitrocellulose membranes (Bio-Rad
Laboratories), which were blocked with 5% milk for Dectin-1
or TLR2 and 5% BSA for Syk proteins in 1 3 TBST for 1 hour.
The membranes then were incubated with goat anti-human
Dectin-1/CLC7A antibody (R&D Systems, Minneapolis, MN,
USA) at 1:1000 or mouse anti-human TLR2 antibody (Imgenex,
San Diego, CA, USA) at 1:250 diluted in 1% milk in TBS with
0.1% Tween overnight at 48C. The membranes were washed
and incubated for 1 hour at room temperature with rabbit anti-
goat HRP (Santa Cruz Biotechnology) or goat anti-mouse HRP
at 1:4000 (Santa Cruz Biotechnology). For total Syk and p-Syk,
the membranes were incubated in rabbit monoclonal primary
antibodies (Cell Signaling, Davers, MA, USA) at 1 in 1000
dilution at 48C for 48 hours. The membranes then were
washed and incubated for 45 minutes at room temperature
with goat anti-rabbit HRP at 1 in 8000 for p-Syk and 1 in 10,000
for total Syk (Pierce, Waltham, MA, USA). The membranes were
stripped after imaging and blotted for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as a loading control using
mouse anti-GAPDH primary at 1 in 20,000 (Millipore,
Kankakee, IL) and goat anti-mouse HRP (Santa Cruz Biotech-
nology) secondary antibodies.
Immunoreactivity was visualized by enhanced chemilumi-
nescence ECL Prime Western Blot detection kits (GE Health-
care, Piscataway, NJ, USA). Images were captured using an
Alpha Imager documentation system (Alpha Innotec). Densi-
tometry was performed and data analyzed with Alpha Ease FC
software. The densitometry data were expressed as relative
pixel intensity of control, which was normalized to 1.
For flow cytometry hTCEpi cells treated with or without F.
solani, TLR2 siRNA, or nonspecific siRNA were harvested and
centrifuged at 400g for 5 minutes to generate a cell pellet. Cells
(800,000) were blocked with 10% human serum (Sigma-
Aldrich Corp., St. Louis, MO, USA) for 15 minutes, permeabi-
lized, and fixed for 20 minutes using Cytofix/Cytoperm (BD
Pharmingen, San Diego, CA, USA). Cells were washed and
incubated with 2 lg/100 lL cell suspension mouse anti-human
TLR2 antibody (Novus, Littleton, CO, USA) or mouse IgG2a as
isotype control for 1 hour at 48C. The cells then were
incubated with anti-mouse IgG Alexa Fluor 488 (Molecular
Probes, Eugene, OR, USA) at 1:300 for 30 minutes at 48C. The
samples were evaluated using a FACS Canto II (BD Biosciences,
San Jose, CA, USA) and the data were analyzed using BD
FacsDiva software (BD Biosciences).
Antifungal Assay
The antimicrobial activity of antimicrobial agent free culture
supernatant harvested from hTCEpi cells treated with heat-
inactivated F. solani, Zymosan, or Zymosan Depleted was
tested against F. solani based on a previously described
protocol.18 Briefly, after 24 hours of treatment the culture
media were collected, then centrifuged at 1400g for 2 minutes.
One mL of the supernatant was incubated with freshly
prepared F. solani at 308C with shaking at 250 rpm for 4
hours; the culture media from untreated cells was used as
control. At the end of the incubation, 10-fold serial dilutions
were plated on SD agar plates and digital images were captured
using an Alpha Imager documentation system and the number
of CU counted after 48 hours of incubation.
To investigate the involvement of specific AMPs in the
antifungal activity that was detected additional experiments
were performed in which culture media from hTCEpi cells
treated with heat-inactivated F. solani, Zymosan, or Zymosan
Depleted was first incubated with antibody against LL37 (1 in
200, donated by R. Lehrer) or hBD2 (25 lg/mL; PeproTech,
Rocky Hill, NJ, USA) or normal rabbit serum (control for LL37;
Sigma-Aldrich Corp.) or goat IgG (control for hBD2; Santa Cruz
Biotechnology) overnight at 48C. The culture media then were
incubated with F. solani, plated, and CU counted after 48
hours as described above.
Statistical Analysis
Multiple comparisons were made using ANOVA in conjunction
with a Tukey’s honestly significant difference (HSD) test to
report mean differences. All experiments presenting quantita-
tive data were repeated at least three times, except where
stated, to ensure reproducibility. A P value <0.05 was
considered statistically significant.
RESULTS
AMP Expression Following F. solani Challenge in
Human Corneal Epithelial Cells
Figure 1A shows the relative fold change in hBD-1, -2, -3, and
LL37 mRNA expression at 6, 12, and 24 hours after challenge
with heat-inactivated F. solani in hTCEpi cells. hBD-2, -3, and
LL37 expression was upregulated at all time points after
challenge compared to control. Peak increases were at 6 hours
after challenge with the levels of mRNA expression decreasing
thereafter. AMPs hBD2 and LL37 showed statistically significant
upregulation by 107.02 6 3.3-fold and 77.24 6 2.2-fold
respectively, compared to untreated control (P < 0.0001) after
6 hours of F. solani treatment. Although increased, expression
of hBD3 at all time points and that of hBD2 and LL37 at 12 and
24 hours was not statistically significantly upregulated.
Expression of hBD1 was not changed at any time point.
Protein expression of hBD2 and LL37 was examined in cell
culture supernatant by immunoblotting. As shown in Figure 1B
there was an increase in the secretion of hBD2 and LL37
protein in F. solani-treated cells, findings in keeping with the
mRNA analysis. Candida albicans–treated hTCEpi cells were
used as a positive control as previous studies have demon-
strated AMP modulation by this fungus.31 Figure 1C shows
normalized densitometry findings from the immunoblots
demonstrating an increase in hBD2 protein by 18.33 6 4.3-
fold and 3.56 6 1.75-fold and LL37 protein by 4.01 6 0.8-fold
and 3.03 6 0.5-fold in F. solani– and C. albicans–treated cells
compared to untreated control, respectively. Upregulation of
hBD2 and LL37 expression was confirmed in primary cultured
HCECs following F. solani challenge as shown in Figure 2F.
Time-Dependent Expression of AMPs in PAMP-
Treated Human Corneal Epithelial Cells
Figure 2 shows hTCEpi cell upregulation of AMPs following
treatment with fungal PAMPs, Zymosan (an agonist that acts
directly and preferentially on TLR2, although is known to
stimulate TLR2 and Dectin-132,33), Zymosan Depleted (Dectin-1
agonist only), or the combination of the two. Initial experi-
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ments performed using increasing concentrations of PAMPs or
the combination did not show a prominent concentration-
dependent effect (data not shown). Therefore in all subsequent
experiments cells were treated with 10 lg/ml of PAMPs or the
combination. Interestingly, while we did not observe an effect
of F. solani challenge on hBD1 expression (Fig. 1), 6 and 12
hours of treatment with Zymosan Depleted resulted in an 82.8
6 39.4– and 34.0 6 5.3–fold (P < 0.05) increase, respectively,
while the combination showed a 289.9 6 2.0– and 49.6 6
12.1–fold (P < 0.001, 0.02 respectively) increase in hBD1
compared to control (Fig. 2A). hBD1 expression also was
enhanced by Zymosan challenge alone at 6 and 12 hours but
this did not reach statistical significance. hBD2 expression (Fig.
2B) was significantly increased 6 hours after treatment with
Zymosan, Zymosan Depleted, and the combination of the two:
50.0 6 9.9, 37.1 6 9.8, 450.1 6 94.1 (P < 0.05, 0.05, and
0.001 respectively). At 12 hours after Zymosan treatment levels
of hBD2 had returned to baseline, whereas those in Zymosan
Depleted and PAMP combination-treated cells remained
elevated. hBD3 (Fig. 2C) expression was statistically signifi-
cantly increased by Zymosan, Zymosan Depleted, and the
combination at 6 hours by 49.5 6 2.7, 248.6 6 72.1, and 228.3
6 35.8 (P < 0.02, 0.001, 0.001) but by 12 hours only levels in
cells treated with the combination remained significantly
elevated (100.7 6 11.6–fold), although less than at 6 hours
and these returned to baseline by 24 hours. In keeping with
the trends in defensin expression changes, LL37 (Fig. 2D)
peaked at 6 hours and was trending toward baseline at 24
hours. Zymosan, Zymosan Depleted, and the combination of
the two resulted in a 78.2 6 2.7–, 183.4 6 0.97–, and 408.9 6
107.3–fold increase compared to untreated control (P < 0.001,
P < 0.0001, P < 0.001), respectively. Only the combination of
Zymosan and Zymosan Depleted showed a statistically
significant 99.0 6 3.3–fold increase at 12 hours (P < 0.01).
FIGURE 1. AMP expression in F. solani treated hTCEpi. (A) AMP expression determined 6, 12, and 24 hours after treatment with F. solani indicated
significant upregulation of hBD2 and LL37 following 6 hours of treatment with levels decreasing thereafter. Data are mean 6 SEM and represent an
average of four independent experiments/time point. *Significant difference compared to untreated control, P  0.05. (B) Representative images
demonstrating an increase in hBD2 and LL-37 protein expression following 24 hours of treatment with heat-killed F. solani (FS) or C. albicans (CA;
as positive control) compared to untreated control (C). The data are representative of three separate experiments. (C) Densitometry of the
immunoblots confirmed upregualtion of hBD2 and LL37 protein following F. solani and C. albicans treatment. Data are mean 6 SEM and represent
an average of three independent experiments.
FIGURE 2. HCEC AMP mRNA Expression is upregulated by Zymosan (Z), Zymosan Depleted (ZD) alone, and in combination (ZþZD). hTCEpi were
exposed to Z, ZD, ZþZD for 6, 12, and 24 hours, then hBD-1 (A), hBD-2 (B), hBD-3 (C), and LL37 (D) expression was determined by RT-PCR. Peak
increases in expression were typically at 6 hours with levels trending toward baseline at subsequent time points. Data are mean 6 SEM and
represent an average of three to five independent experiments. *Significant difference compared to untreated cells, P  0.05. (E) Increased
secretion of hBD2 and LL37 in to the culture media also was detected 24 hours after challenge with Z, ZD, ZþZD. Data are representative of three
independent experiments. (F) Primary human corneal epithelial cells treated with heat-killed F. solani, and Z, ZD, ZþZD demonstrated an increase
in hBD2 and LL37 expression compared to untreated cells following 6 hours of treatment. Data are mean 6 SEM and represent an average of three
individual experiments. *Significant difference, P  0.05. (G) Quantification of hBD2 and LL37 protein in primary HCECs by immunoblot showed an
increase in F. solani-treated cells but no significant increase in PAMP-treated cells. Data are mean 6 SEM and represent an average of three individual
experiments.
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Overall peak upregulation of AMP mRNA was typically at 6
hours after which time levels began to fall and were almost
back to baseline by 24 hours. At 6 hours after treatment AMP
mRNA upregulation was significantly greater with the combi-
nation of PAMPs compared to either Zymosan or Zymosan
Depleted challenge alone (P < 0.001) with the exception that
for hBD3 this applied only to the comparison of the PAMP
combination to Zymosan alone (P < 0.02). Cells treated with
the PAMPs for 24 hours also showed an increase in hBD2 and
LL37 protein secretion compared to nontreated cells (Fig. 2E).
Quantitation (not shown) of the secreted hBD2 and LL37 in
hTCEpi cells was consistent with the representative immuno-
blot images. To confirm that similar effects also were seen in
primary cultured HCEC, AMP expression was determined
following 6 hours of treatment with heat-killed F. solani,
Zymosan, Zymosan Depleted, or the combination of the two.
As shown in Figure 2F there was upregulation of all AMPs
tested. Statistically significant upregulation was observed for
hBD2 and LL37 with all of the treatments. Increases of 8.0 6
1.9– and 5.5 6 0.2–fold compared to control (P < 0.008,
0.004) were observed following treatment with heat-inactivat-
ed F. solani for hBD2 and LL37 respectively. Treatment with
Zymosan resulted in an upregulation of hBD2 and LL37 by 5.9
6 0.7– and 5.5 6 0.1–fold, Zymosan Depleted by 6.9 6 0.4–
and 5.2 6 0.5–fold, and the combination by 7.1 6 1.5– and 7.3
6 2.2–fold compared to untreated control (P < 0.03, 0.04,
0.004). Although expression of hBD-1 and -3 was increased,
this only reached statistical significance for hBD1 in cells
exposed to the combination of Zymosan and Zymosan
Depleted. AMP secretion was determined by immunoblotting
following 24 hours of incubation with F. solani and PAMPs and
showed similar results to those of hTCEpi cells although the
intensity of staining was much lower, which is in keeping with
the lower levels of AMP mRNA expression observed in primary
cultured cells compared to the cell line. Relative densitometry
of AMP protein levels in cell supernatant of primary HCECs is
shown in Figure 2G. Data confirmed an increase in hBD2 and
LL37 by 8.58 6 1.4– and 2.45 6 0.7–fold in F. solani-treated
cells respectively, although there was minimal detectable
protein upregulation in response to PAMPs.
Modulation of AMP Expression by TLR2
As AMP expression is known to be modulated by TLR activation
and previous studies have suggested that TLR2 is an important
fungal PRR, we sought to determine if it is involved in F. solani-
induced AMP expression in hTCEpi cells by knocking down its
expression by siRNA. As shown in Figure 3A, 3 different siRNA’s
#1, 2, and 3 (s167, s168, and s170) were tested and resulted in a
45%, 67%, and 72% decrease, respectively, in TLR2 mRNA
expression compared to control. The effectiveness of knock-
down by siRNA #3 (s170) then was confirmed by relative
quantitative RT-PCR as shown in Figure 3B, where a 76% 6 12%
decrease in TLR2 mRNA levels was found. Reduction in TLR2
protein expression when cells were transfected with siRNA #3
(s170) was confirmed by Western blotting (Fig. 3C) and flow
FIGURE 3. Modulation of AMP expression by fungal activation of TLR2 in hTCEpi cells. (A) One-step RT-PCR was used to determine TLR2
knockdown by a series of siRNAs. NS, nonspecific siRNA; #1, #2, and #3, three different TLR2 specific siRNAs. Data are representative of three
independent experiments with comparable results. (B) Confirmation via real-time relative RT-PCR indicated a significant decrease in TLR2 mRNA
expression in siRNA #3–treated cells compared to the NS-treated cells. Data are expressed as relative quantity compared to control 6 SEM from 3
separate experiments. *Significant difference (P < 0.01) compared to untreated control. (C) Western blotting also showed a marked decrease in
TLR2 expression following 48 hours of treatment with TLR2 siRNA #3 compared to NS siRNA. GAPDH was used as a loading control as indicated.
The data are representative of four independent experiments. (D) Flow cytometry in TLR2 siRNA– and NS siRNA–treated cells demonstrated a
decrease in TLR2 expression in cells treated with the specific siRNA. Data are representative of three independent experiments. (E) siRNA #3 was
used to knockdown TLR2 then cells were stimulated with heat-inactivated F. solani for 6 hours and AMP mRNA expression determined by RT-PCR.
The expression of hBD2 and LL37 mRNA stimulated by F. solani was completely abrogated by TLR2 knockdown. Data are expressed as relative
quantity change compared to control 6 SEM from 5 separate experiments. *Significant difference compared to NS siRNA. (F) siRNA #3 was used to
knockdown TLR2 then cells were stimulated with heat-inactivated F. solani for 24 hours. Immunoblotting then was performed and showed a
decrease in hBD2 and LL37 secretion in TLR2 siRNA-treated cells. These data are representative of three or four independent experiments with
comparable findings. NS, nonspecific siRNAþ F. solani; TLR2, TLR2 siRNAþ F. solani. (G) Quantification of the hBD2 and LL37 immunoblots by
densitometry. Data are mean 6 SEM and represent an average of three individual experiments.
Role of PRRs in F. solani Induced AMP Expression IOVS j May 2017 j Vol. 58 j No. 5 j 2467
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936209/ on 05/19/2017
cytometry (Fig 3D). This siRNA#3 (s170) then was used in
subsequent experiments. The effects of TLR2 knockdown on
AMP expression are shown in Figures 3E and 3F. Figure 3D
demonstrates flow cytometry data indicating a knockdown of
TLR2 in siRNA treated hTCEpi cells compared to nonspecific
siRNA-treated cells. As seen previously (Fig. 1), exposure to heat-
inactivated F. solani stimulated hBD2 and LL37 mRNA
expression (by 84.9– and 68.5–fold respectively, P < 0.0001,
0.0001) and in these experiments this was completely abrogated
(P < 0.0001, 0.0001) in cells in which TLR2 had been knocked
down by siRNA (Fig. 3E). Nonspecific siRNA did not significantly
interfere with the ability of heat-inactivated F. solani to stimulate
AMP expression. Figure 3F (immunoblotting) and quantitation
by densitometry (Fig. 3G) confirms reduction of F. solani-
stimulated hBD2 and LL37 secretion in to the culture media in
cells treated with the TLR2-specific siRNA versus the nonspe-
cific siRNA.
Dectin-1 Mediated Modulation of AMP Expression
Using Syk Inhibitor
First the presence of Dectin-1 was confirmed in the hTCEpi
cell line using primary cultured HCEC as a positive control.23
As shown in Figure 4A, primary cultured HCEC and hTCEpi
cells expressed mRNA for the 2 isoforms of Dectin-1 (major
207 and minor 345 base pairs [bp]) and Dectin-1 protein
expression was detectable in cell lysates. To determine the role
of Dectin-1 in F. solani-induced AMP expression, we used BAY
61-3601 to block Syk signaling. Quantitation of hBD2 and LL37
mRNA as demonstrated in Figure 4B indicated that exposure to
F. solani or Zymosan or Zymosan Depleted showed a
significant upregulation of hBD2 and LL37 as we had seen
previously. However, pretreatment of cells with BAY 61-3601
followed by stimulation with F. solani, Zymosan, or Zymosan
Depleted resulted in significantly decreased expression of
hBD2 by 4.8-, 31.2-, and 59.2–fold (P < 0.001, 0.01, and 0.001)
and LL37 by 2.2-, 2.8-, and 5.5-fold (P < 0.04, 0.04, and 0.01),
respectively. Data in Figure 4C show that exposure to BAY 61-
3601 followed by treatment with heat-killed F. solani,
Zymosan, or Zymosan Depleted results in reduced secretion
of hBD2 and LL37 compared to their respective controls. hBD2
secretion induced by heat-killed F. solani, Zymosan, and
Zymosan Depleted was reduced by 26.9% 6 0.2%, 55.0% 6
11.4%, and 43.8% 6 15.8%, respectively. Similarly, there was a
decrease in LL37 secretion in BAY 61-3601 pretreated heat-
killed F. solani, Zymosan, and Zymosan Depleted treated
samples of 35.0% 6 7.6%, 46.2% 6 2.4%, and 50.7% 6 4.4%,
respectively (mean 6 SD). Figure 4D shows quantitative
densitometry data for hBD2 and LL37 protein expression in
F. solani- and PAMP-treated cells. These data demonstrated that
exposure to BAY 61-3601 decreased hBD2 and LL37 expression
compared to stimulated controls, although due to variability
this did not reach statistical significance. Figure 4E shows
upregulation of p-Syk in F. solani-treated cells compared to
control. Pretreatment with BAY 61-3601 decreased the
expression of p-Syk stimulated by F. solani, indicating a critical
role played by the Syk pathway in AMP upregulation following
fungal treatment.
FIGURE 4. BAY 61-3601, a Syk pathway inhibitor, attenuates fungal and PAMP-stimulated AMP expression by hTCEpi cells. (A) One-step RT-PCR and
Western blotting showed that primary cultured HCEC and hTCEpi cells had robust expression of Dectin-1 (major isoform 207 bp, minor 345 bp) at
the mRNA (upper) and protein level (lower). Data are representative images from three independent experiments. hTCEpi cells were treated with
Syk inhibitor BAY 61-3601 for 48 hours then stimulated with heat-killed F. solani or PAMPs for 6 hours (mRNA) or 24 hours (protein) and AMP
expression determined by RT-PCR (B) and immunoblotting (C). Pretreatment with BAY 61-3601 (BAY) reduced F. solani (FS)/PAMP-induced AMP
expression. In (B) data are expressed as relative quantity change compared to control 6 SEM from 3 separate experiments. *Upregulation of hBD2
and LL37 compared to untreated or BAY treated control. þþ, Significant downregulation following BAY treatment compared to their respective
controls. Immunoblot data (C) are representative of two and three independent experiments for hBD2 and LL37, respectively. (D) Relative
densitometry data for hBD2 and LL37 protein in F. solani- and PAMP-treated cells. (E) Western blotting for total and p-Syk demonstrated an increased
in p-Syk in F. solani–treated cells compared to control (C) which was abrogated by treatment with BAY. GAPDH was used as the loading control.
Data are representative of three independent experiments.
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Modulation of AMP Expression by Knocking Down
Dectin-1 Receptor
To confirm the specific involvement of Dectin-1 suggested by
our experiments inhibiting the Syk pathway, siRNA was used to
knockdown expression of Dectin-1 and AMP expression in F.
solani-treated hTCEpi cells determined. As depicted in Figure
5A, hTCEpi cells were treated with Dectin-1 siRNAs or
nonspecific siRNA. The expression of Dectin-1 was significant-
ly knocked down by 70.2% 6 5.8%, 67.6% 6 2.8%, and 77.8%
6 3.1% by the three siRNAs (#1-s34783, #2-s34785, and #3-
s227204), respectively. Further, confirmation of the knock-
down by siRNA #3- s227204 as evaluated by relative
quantitative RT-PCR demonstrated a 75.9% 6 7.8% knockdown
as shown in Figure 5B. Therefore, siRNA #3-s227204 was used
in subsequent experiments. Figure 5C confirms the decrease in
Dectin-1 expression at the protein level following treatment
with Dectin-1 siRNA compared to nonspecific siRNA. As
demonstrated in Figure 5D heat-inactivated F. solani and
nonspecific siRNA treatment before F. solani stimulated
expression of hBD2 and LL37 as seen previously. Silencing
Dectin-1 significantly decreased the F. solani stimulated
expression of hBD2 from 17.4 6 0.7 to 6.4 6 4.4 and of
LL37 from 15.0 6 0.9 to 1.4 6 0.2 at the mRNA level (P < 0.04
and 0.0001). Representative immunoblots and densitometry
analysis for hBD2 and LL37 in Dectin-1 siRNA– and nonspecific
siRNA–treated cells are shown in Figures 5E and 5F, respec-
tively. The data demonstrated that Dectin-1 knockdown
decreased hBD2 and LL37 expression compared to nonspecific
siRNA-treated control.
Functional Significance of F. solani Induced hBD2
and LL37 Secretion
To determine if the observed upregulation and enhanced
secretion of hBD2 and LL37 was of functional significance,
supernatants from hTCEpi cells treated with F. solani,
Zymosan, or Zymosan Depleted were incubated with live F.
solani and the percent killing by the culture supernatants was
determined. As shown in Figure 6A supernatants from heat-
killed F. solani, Zymosan, and Zymosan Depleted treated cells
showed significantly increased killing of F. solani by 58.4% 6
4.0%, 82.7% 6 6.0%, and 90.5% 6 4.2%, respectively (P <
0.0001) compared to control (culture media from untreated
cells). We then performed additional experiments in the
presence of antibodies to block hBD2 and LL37 antimicrobial
activity. Figure 6B shows that blocking hBD2 activity in
supernatant from fungal or PAMP-stimulated cells decreased
the percent killing of F. solani by 83.2% 6 6.5%, 67.1% 6
5.6%, and 82.1% 6 4.8% (P < 0.002, 0.01, 0.002) compared to
the respective IgG controls. Similarly, as shown in Figure 6C,
the presence of LL37 antibody decreased percent killing by
99.3% 6 5.9%, 98.9% 6 3.3%, and 84.7% 6 5.8% (P < 0.0001,
0.0001, 0.001) compared to the serum control.
FIGURE 5. Dectin-1 knockdown attenuates fungal stimulated AMP expression by hTCEpi cells. (A) One step RT-PCR was used to determine Dectin-1
knockdown by a series of siRNAs after 48h. All of the siRNAs were effective and #3 (s227204) was selected for further study. The data are
representative of three independent experiments. (B) Relative quantitative RT-PCR confirmed efficient knockdown of Dectin-1 by siRNA s227204.
Data are expressed as relative quantity change compared to control 6 SEM from 4 separate experiments. (C) Western blotting also showed a
decrease in Dectin-1 protein expression compared to NS siRNA with b-Actin as the loading control. The data are representative of two independent
experiments. (D) Following knockdown of Dectin-1 the cells were stimulated with heat-inactivated F. solani and AMP mRNA expression determined
by RT-PCR. The expression of hBD2 and LL37 mRNA stimulated by F. solani was significantly decreased compared to NS siRNA-treated cells. Data
are expressed as relative quantity change compared to control 6 SEM from 5 separate experiments. *Significant difference compared to nonspecific
siRNA. (E) Immunoblotting for AMPs, hBD2, and LL37 in F. solani stimulated cells following Dectin-1 or nonspecific siRNA treatment. Dectin-1
siRNA knockdown resulted in decrease in hBD2 and LL37 secretion. These data are representative of three to four independent experiments with
comparable findings. (F) Shows relative densitometry data for the immunoblots showing reduced hBD2 and LL37 expression.
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DISCUSSION
F. solani is a major cause of mycotic keratitis resulting in visual
impairment and blindness worldwide; however, the intricate
mechanisms of the host-immune response to this pathogen
invading the cornea are not well established. Although recent
studies have addressed the role of various PRRs, including TLRs
and Dectin-1 in fungal keratitis, the precise mechanism
involved still remains elusive.27,34–37 Collectively, results from
this investigation demonstrated that Dectin-1 and TLR2 are
vital PRRs expressed in HCEC. Our findings showed that
PAMPs associated with F. solani upregulate AMPs hBD2 and
LL37 at the mRNA and protein level via a TLR2- and Dectin-1–
mediated mechanism. Furthermore, our data also revealed that
hBD2 and LL37 have functional significance as they mediate
the antifungal activity of culture supernatants from F. solani
and PRR agonist–treated HCEC.
A number of previous studies have shown upregulation of
AMPs in response to fungal exposure in several cell types,
including HCEC in which hBD-2, -3, and LL37 were upregu-
lated in response to C. albicans and A. fumigatus in vitro.31,38
The cathelicidin CRAMP also was reported to be upregulated in
a murine model of Candida keratitis.39 We have shown that
several b-defensins and CRAMP are elevated in a murine model
of Fusarium keratitis,15 but there have been no comprehen-
sive studies investigating the complement of AMP expression
in HCEC in response to F. solani. We found exposure to this
fungal pathogen significantly and reproducibly increased
expression of hBD2 and LL37 in a human corneal epithelial
cell line and we confirmed this in primary cultured cells. AMP
mRNA levels peaked at 6 hours, then began to decline but
elevated AMPs were detected in the culture media 24 hours
later. We also showed that fungal glucan (in the form of
Zymosan or Zymosan Depleted) initiated the enhanced AMP
expression. HCEC expression of two defensins, hBD1 and
hBD3, was not significantly upregulated by F. solani but
marked increases were apparent when the cells were
challenged with PAMPS alone or in combination. These
findings may be because of the presence of highly concentrat-
ed PAMPs in the purified compounds compared to heat-
inactivated F. solani. Interestingly, the combination of Zymo-
san and Zymosan Depleted demonstrated a significant upreg-
ulation of AMPs tested compared to individual PAMP treatment
after 6 hours. Generally, this was more than a simple additive
effect indicating cooperation among TLR2 and Dectin-1, the
two primary targets for these PAMPs. We also observed that
while the trends of AMP upregulation were similar between
the hTCEpi cell line and primary cultured cells, the relative fold
changes seen in the primary cultured cells were much lower
compared to the cell line. As far as possible, we confirmed our
mRNA expression findings at the protein level and quantitated
the immunoblots by densitometry. However as AMPs are
challenging to detect owing to their small size, relatively low
expression and lack of optimal antibodies, these data, in
contrast to the mRNA, often did not show statistically
significant changes, although the trends were the same.
As previous studies have reported the involvement of TLRs,
particularly TLR-2 and -4 and Dectin-1 in fungal effects caused
by A. fumigatus, C. albicans, F. solani,27,33,40–42 we sought to
address the role of these PRRs in mediating the upregulation of
AMPs in F. solani challenged HCEC. We focused on involve-
ment of TLR2 and Dectin-1, as expression of functional TLR4
and its necessary accessory molecules in HCEC have been
questioned and studies with our cultured cells failed to show a
robust response to the classic TLR4 ligand lipopolysaccharide
(data not shown).43,44 Data from our investigation showed that
hTCEpi cells and primary cultured HCEC expressed PRRs
Dectin-1 and TLR2 at mRNA and protein levels as demonstrated
by PCR, and Western blot. Human corneal epithelial cell TLR2
expression has been documented in a number of studies16 but
few studies have addressed Dectin-1 expression in cultured
HCECs. Hua et al.24 showed that Dectin-1 was expressed in the
epithelium of human corneal tissue sections and in primary
cultured human corneal limbal epithelial cells.24 Interestingly,
their study also showed upregulation of Dectin-1 following
exposure to heat-killed C. albicans. Another recent study
reported the expression of Dectin-1 in an unspecified corneal
epithelial cell line and in corneas from patients with fungal
keratitis.23 Our data confirm the expression of Dectin-1 in
primary cultured HCEC and reveals its expression by a
telomerase modified cell line. We also observed Dectin-1
expression (data not shown) in SV40 immortalized HCECs.45
Dectin-1 signaling involves Syk or CARD as reported by
Poeck et al.46 To study the involvement of Dectin-1 in AMP
modulation, a potent pharmacologic Syk inhibitor BAY 61-3606
was added before agonist treatment.47 Under these conditions,
AMP expression was significantly decreased indicating that AMP
modulation occurs via a Syk-mediated mechanism. We also used
FIGURE 6. Functional significance of F. solani induced AMP upregulation. (A) Antifungal assays were performed using culture supernatants from
hTCEpi cells treated with heat-killed F. solani or PAMPs for 24 hours. *Significant increase in percent killing compared to control. Specific antibodies
to hBD2 (B) and LL37 (C) were used to block the antimicrobial activities of these AMPs, under which circumstances the killing activity of the culture
supernatants was lost. *Significant decrease in percent killing compared to the respective control. All data are mean 6 SEM from three to four
separate experiments.
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siRNA to knockdown Dectin-1 expression and confirmed that it
is necessary for F. solani-stimulated AMP upregulation in HCEC.
Here, we also have shown that blocking TLR2 expression using
specific siRNA significantly decreased the F. solani-mediated
increase in expression of hBD2 and LL37. Thus, Dectin-1 and
TLR2 can mediate the effects of F. solani on AMP expression in
HCEC. Although we were not able to study involvement of TLR4
in our specific cells, based on observations in other studies27,42
this PRR also is likely to be involved in the ocular surface
epithelial response to F. solani in vivo.
Having shown that F. solani and PAMPs stimulated HCEC
secretion of AMPs hBD2 and LL37, we also studied the
functional significance of this via antifungal assays. We
observed that blocking the activity of hBD2 or LL37 using
specific antibodies significantly decreased the antifungal
activity of the cell culture supernatant collected from F.
solani-treated cells. Interestingly, addition of either AMP
antibody was able to completely block the antifungal activity,
suggesting that hBD2 and LL37 in the culture media cooperate
to achieve effective killing of F. solani. This is in keeping with
many previous studies, which have suggested that AMP
antimicrobial activity is due in large part to cooperative
interactions among two, or possibly more AMPs.
Overall our data suggested that AMPs, hBD2 and LL37 in
particular, upregulated via TLR2 and Dectin-1 in response to F.
solani, have functional antifungal activity that will help
facilitate eradication of fungal pathogens and that corneal
epithelial cells are active participants in the ocular surface
innate defense against fungal keratitis.
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